Genzyme Renagel
Executive Summary
Physicians should shift patients to 400 mg sevelamer tablets or 403 mg capsules during period of short supply of 800 mg tablets, which the company attributes to increased demand. Supply of the phosphate-reducing agent is "sufficient to meet the current demand and growth requirements over the next several years," company says. Genzyme is expanding a manufacturing plant in Haverhill, U.K., which will provide additional supplies beginning in 2002. Genzyme expects Renagel sales of $120 mil.-$130 mil. in 2001 (1"The Pink Sheet" Sept. 18, 2000, p. 28)